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Abstract
Background: BRCA1 and BRCA2 mutations have been associated with prostate cancer
(PCa) risk but a wide range of risk estimates have been reported that are based on
retrospective studies.
Objective: To estimate relative and absolute PCa risks associated with BRCA1/2 muta-
tions and to assess risk modiﬁcation by age, family history, and mutation location.
Design, setting, and participants: This was a prospective cohort study ofmale BRCA1 (n =
376) and BRCA2 carriers (n = 447) identiﬁed in clinical genetics centres in the UK and
Ireland (median follow-up 5.9 and 5.3 yr, respectively).
Outcome measurements and statistical analysis: Standardised incidence/mortality ra-
tios (SIRs/SMRs) relative to population incidences or mortality rates, absolute risks, and
hazard ratios (HRs) were estimated using cohort and survival analysis methods.
Results and limitations: Sixteen BRCA1 and 26 BRCA2 carriers were diagnosed with PCa
during follow-up. BRCA2 carriers had an SIR of 4.45 (95% conﬁdence interval [CI] 2.99–
6.61) and absolute PCa risk of 27% (95% CI 17–41%) and 60% (95% CI 43–78%) by ages
75 and 85yr, respectively. For BRCA1 carriers, the overall SIRwas 2.35 (95% CI 1.43–3.88);
the corresponding SIR at age<65yr was 3.57 (95% CI 1.68–7.58). However, the BRCA1 SIR
varied between 0.74 and 2.83 in sensitivity analyses to assess potential screening effects.
PCa risk for BRCA2 carriers increased with family history (HR per affected relative 1.68,
95% CI 0.99–2.85). BRCA2 mutations in the region bounded by positions c.2831 and
c.6401 were associated with an SIR of 2.46 (95% CI 1.07–5.64) compared to population
incidences, corresponding to lower PCa risk (HR 0.37, 95% CI 0.14–0.96) than for
mutations outside the region. BRCA2 carriers had a stronger association with Gleason
score 7 (SIR 5.07, 95% CI 3.20–8.02) than Gleason score 6 PCa (SIR 3.03, 95% CI 1.24–
7.44), and a higher risk of death from PCa (SMR 3.85, 95% CI 1.44–10.3). Limitations
include potential screening effects for these known mutation carriers; however, the
BRCA2 results were robust to multiple sensitivity analyses.
Conclusions: The results substantiate PCa risk patterns indicated by retrospective
analyses for BRCA2 carriers, including further evidence of association with aggressive
PCa, and give some support for a weaker association in BRCA1 carriers.
Patient summary: In this study we followed unaffected men known to carry mutations
in the BRCA1 and BRCA2 genes to investigate whether they are at higher risk of
developing prostate cancer compared to the general population. We found that carriers
of BRCA2 mutations have a high risk of developing prostate cancer, particularly more
aggressive prostate cancer, and that this risk varies by family history of prostate cancer
and the location of the mutation within the gene.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Deleterious mutations in the tumour suppressor genes
BRCA1 and BRCA2 are associated with high risks of breast
and ovarian cancer [1,2], and have been implicated in the
genetic susceptibility to prostate cancer (PCa). Retrospective
studies have reported that BRCA2 mutations are associated
with relative risks (RRs) of PCa in the range 2–6 [80_TD$DIFF] 3–13]. RR
estimates reportedwerehigher foryoungerages, in the range
6–9 for those aged <65yr [81_TD$DIFF] 4,6,13–15], and BRCA2 carriers
presentmore oftenwith aggressive PCa [82_TD$DIFF] 8,9]. The evidence of
association between BRCA1 mutations and PCa risk is
inconsistent, with reported RRs in the range [83_TD$DIFF]0.3–4 [3,5,7–
10,12,13,16–20]. A recentmeta-analysis reported a moderate
association between BRCA1 mutations and PCa risk [84_TD$DIFF](pooled
odds ratio 1.35, 95% CI 1.03–1.76) [3], but two studies have
reported [85_TD$DIFF]RRs of 2–4 for BRCA1 carriers younger than 65yr [86_TD$DIFF]
[17,21]. Studies have also reported variation in PCa risk by
mutation location and type [87_TD$DIFF] 6,8,10,13,22,23].
There are only a few estimates of absolute risks of PCa for
BRCA1/2mutationcarriersandthosearebasedonretrospectivestudies [88_TD$DIFF] 4,6,7,13,15,17,21,22]. Given the rapidly rising incidence
of PCa in the prostate-specific antigen (PSA) testing era,
retrospectiveabsoluteriskestimatesmaynotberepresentative
of the risks for mutation carriers currently seen in genetics
clinics. Only two small prospective cohort studies of male
BRCA1/2 carriers have been reported [89_TD$DIFF] 12,24], the largest of
which followed137BRCA1and71BRCA2 carriers foranaverage
of 5.1yr, and did not show an association with PCa [90_TD$DIFF] 24].
In the present study, we report age-specific PCa risk
estimates for a large prospective cohort of male BRCA1 and
BRCA2 carriers. We present relative and absolute risks,
investigate variability in these risks by family history and
mutation location, and consider the risk of developing high-
grade PCa.
2. Patients and methods
2.1. EMBRACE study participants
EMBRACE (http://ccge.medschl.cam.ac.uk/embrace/) is a
cohort study of BRCA1 and BRCA2mutation carriers initiated
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centres across the UK and Ireland, andwere counselledwith
regard to their mutation status. This analysis included all
male participants without a PCa diagnosis at recruitment
who carried mutations considered to be pathogenic on the
basis of widely accepted criteria (ENIGMA consortium;
https://enigmaconsortium.org/). All participants completed
a baseline questionnaire that included information on
known and suspected cancer risk factors, medical history,
and personal and family cancer history. Follow-up data
were collected through linkage with national registers
covering England, Wales, and Scotland, and questionnaires [91_TD$DIFF]
that were collected at 2, 5, and 10 yr after baseline. For self-
reported cancers, confirmation was sought from the
participating clinics. For the present study, the end of
follow-up was set as June 30, 2016 to ensure that cancer
diagnoses were likely to have been reported at the time of
the last record linkage (performed on October 4, 2016) or as
the date of the last questionnaire returned if one was
available after June 30, 2016.
All participants provided written informed consent. The
study was approved by the Anglia and Oxford Medical
Research and Ethics Committee.
2.2. Statistical analysis
We prospectively followed the participants from comple-
tion of their baseline questionnaire until their age at
diagnosis of PCa, age of death, age at the end-of-follow-up,
or age 85 yr, whichever occurred first. A diagnosis of another
cancer or of prostatic intraepithelial neoplasia was not
considered as a censoring event. Analogously, we followed
the participants for deaths due to PCa.
We compared the observed PCa incidence and PCa
mortality to those expected frompopulation incidences and
PCa-specific mortality rates (Office for National Statistics,
https://www.ons.gov.uk/) using standardised incidence
ratios (SIRs) or standardised mortality ratios (SMRs)
computed via Poisson regression. We used the Kaplan-
Meier estimator to estimate absolute risks, and Cox
regression to test for differences in risk between subgroups.
We classified men who had at least one first- or second-
degree relative diagnosed with PCa as having a positive PCa
family history, and assessed trends in risks according to the
number of affected relatives. We investigated differences in
risk by mutation position using prespecified definitions of
regions for which different associations with PCa risk have
been identified in published studies [92_TD$DIFF] 6,10,13,22,23]. To
assess the association of BRCA1/2 mutations with clinical
PCa subtypes according to biopsy Gleason score (GS), we
compared the observed number of PCa diagnoses by GS
subtype to those expected given population GS-specific
incidences. We used competing risk estimators to estimate
the absolute risk for these clinical subtypes. Because data on
GS were not available for all PCas, we used multiple
imputation to avoid omission of PCa events.
For the main analysis, we included men with previous
non-prostate cancers, did not censor for non-prostate
cancers during follow-up, and considered follow-up up tothe last questionnaire if available after the last record
linkage. We assessed the impact of these assumptions in
sensitivity analyses. We also repeated the analysis after
omitting pathogenic missense mutations to assess the
impact of such less clearly deleterious mutations.
Mutation carriers may be offered a different screening
and diagnosis regimen than men in the general population [93_TD$DIFF]
[25]. We performed further analyses to assess the potential
impact of such differential screening. First, we performed
landmark analyses where follow-up was initiated at 6 or
12 mo after baseline. Second, on the basis of previous
findings that observed PCa incidences are 1.4–1.9 times
higher for men undergoing PSA screening at regular
intervals in comparison to unscreened men [75_TD$DIFF] 26], we
estimated SIRs relative to population incidences multiplied
by adjustment factors of 1.6 and 1.9. To obtain absolute risk
estimates, we used weighted Kaplan-Meier estimators.
Furthermore, in October 2005 the UK-based IMPACT
screening trial started recruiting BRCA1/2 carriers [76_TD$DIFF] 27]. Al-
though the exact overlap between the studies is unclear, to
investigate the impact on risk estimateswe assessed (1) PCa
risks separately for participants from IMPACT-recruiting
centres and their person-time fromOctober 2005 and after;
and (2) the person-time for participants from these centres
before October 2005 in addition to the entire person-time
for participants from non–IMPACT-recruiting centres.
Statistical analysis was performed using R (version 3.4.4;
R Foundation for Statistical Computing, Vienna, Austria).
Full details of all methods are given in the Supplementary
material.3. Results
3.1. Prostate cancer
In total, 16 of 376 BRCA1 and 26 of 447 BRCA2 mutation
carriers were diagnosed with PCa during median follow-up
of 5.9 and 5.3 yr, respectively (Table 1). All PCa diagnoses
were confirmed via either registry linkage or the partici-
pating clinics.
Carrying a BRCA1mutationwas associatedwith a PCa SIR
of 2.35 (95% confidence interval [CI] 1.43–3.88) relative to
the population incidence, whereas the SIR for BRCA2
carriers was 4.45 (95% CI 2.99–6.61). For BRCA1 carriers,
the SIR was 3.57 (95% CI 1.68–7.58) for ages <65yr and 1.86
(95% CI 0.96–3.59) for ages 65yr. The SIR estimates by age
were similar for BRCA2 carriers (3.99, 95% CI 1.88–8.49 for
<65yr; 4.64, 95% CI 2.91–7.41 for 65yr). The estimated
absolute risk of PCa was 21% (95% CI 13–34%) by age 75 yr
and 29% (95% CI 17–45%) by age 85 yr for BRCA1 carriers. The
corresponding PCa risks for BRCA2 carriers were 27% (95% CI
17–41%) and 60% (95% CI 43–78%), respectively (Table 2;
Fig. 1A and 1B).
For men with a positive family history, the SIR was 3.17
(95% CI 0.97–10.37) for BRCA1 and 7.31 (95% CI 3.40–15.72)
for BRCA2 carriers. The corresponding SIRs for carriers
without a family history were 2.34 (95% CI 1.35–4.07) and
3.87 (95% CI 2.40–6.23), respectively. For BRCA2 carriers, the
Table 1 – Participant characteristics.
Parameter Result
Initially recruited[43_TD$DIFF], n 998
Excluded: mutation in both BRCA1 and BRCA2 4
[44_TD$DIFF]BRCA1carriers BRCA2carriers
Initially recruited[43_TD$DIFF], n 451 543
Excluded: variant of unknown signiﬁcance 3 3
Excluded: previous prostate cancer diagnosis 14 37
Excluded: age 85yr at baseline 1 0
Excluded: no follow-up beyond baseline 57 56
[45_TD$DIFF]Men included,na 376 447
Year of study entry, n (%)
1999–2004b 69 (18) 48 (11)
2005–2010 144 (38) 172 (38)
2011–2016 163 (43) 227 (51)
Median age at study entry, yr (interquartile range) 54.0 (43.2–64.1) 51.4 (41.5–63.6)
Age group at study entry, yr, n (%)
19–44 103 (27) 155 (35)
45–54 97 (26) 105 (23)
55–64 96 (26) 102 (23)
65–74 65 (17) 66 (15)
75–83 15 (4.0) 19 (4.3)
Median follow-up, yr (interquartile range)c 5.9 (3.0–10.1) 5.3 (2.6–8.9)
Family history of prostate cancer, n (%)d
No 297 (79) 328 (73)
Yes 48 (13) 87 (19)
Unknown (at least 1 male relative with unknown cancer site) 14 (3.7) 16 (3.6)
Missing data 17 (4.5) 16 (3.6)
Previous non–prostate cancer diagnosis, n (%)
No 355 (94) 390 (87)
Yese 21 (5.6) 57 (13)
Non–prostate cancer diagnosis during follow-up, n (%)
Nof 349 (93) 429 (96)
Yesg[46_TD$DIFF] 27 (7.2) 18 (4.0)
[47_TD$DIFF]Prostate cancer diagnosis[48_TD$DIFF],n 16 26
Median age at prostate cancer diagnosis, yr (interquartile range) 66.0 (61.9–71.7) 71.4 (62.8–77.5)
Diagnostic modality, n (%)
Screening 11 (69) 14 (54)
Clinical symptoms 3 (19) 7 (27)
Missing data 2 (13) 5 (19)
Median PSA at diagnosis, ng/ml (interquartile range) 5.0 (3.6–5.9) 6.2 (4.3–21.6)
Clinical stage, n (%)
T1 1 (6.3) 4 (15)
T2 7 (44) 12 (46)
T3 4 (25) 2 (7.7)
T4 0 (0) 1 (3.8)
TX 1 (6.3) 1 (3.8)
Missing data 3 (19) 6 (23)
Gleason score, n [49_TD$DIFF](%)
6 7 (44) 4 (15)
3 +4 4 (25) 7 (27)
4 +3 0 (0) 3 (12)
8 2 (13) 5 (19)
Missing data 3 (19) 7 (27)
PSA=prostate-speciﬁc antigen.
a BRCA1: 309 singletons, 23 families with two relatives, four families with three relatives, [50_TD$DIFF]one family with four relatives, [51_TD$DIFF]and one family with five relatives. BRCA2:
353 singletons, 36 families with two relatives, six families with three relatives, and one family with four relatives.
b Study recruitment was initiated in August 1998 but the first male participant was recruited in February 1999.
c Calculated using the reverse Kaplan-Meier method.
d At least one first- or second-degree relative diagnosed with prostate cancer.
e Includes four BRCA1 and 35 BRCA2 carriers with male breast cancer.
f Includes three BRCA2 carriers who were diagnosed with high-grade prostatic intraepithelial neoplasia and who did not develop any malignant tumours.
g Includes one BRCA1 and two BRCA2 carriers with male breast cancer, and two BRCA1 and three BRCA2 carriers with pancreatic cancer.
E U RO P E AN U RO LOGY 7 7 ( 2 0 2 0 ) 2 4 – 3 5 27hazard ratio (HR) per affected relative was 1.68 (95% CI
0.99–2.85; Table 2; Fig. 1C and 1D).
Men with BRCA2mutations located in the central region
of the gene (c.2831–c.6401; ovarian cancer cluster region
[OCCR], wide definition [42_TD$DIFF] 2,22]; see Supplementary materialonline) had a significantly lower risk of PCa than men with
mutations outside this region (HR 0.37, 95% CI 0.14–0.96).
However, mutations both within (SIR 2.46, 95% CI 1.07–
5.64) and outside (SIR 5.88, 95% CI 3.75–9.22) the OCCR
were associated with higher [94_TD$DIFF]than population PCa risk.
[(Fig._1)TD$FIG]
Fig. 1 – Absolute prostate cancer risk for BRCA1 and BRCA2 mutation carriers, with the number at risk at each age on the x-axis. (A) Overall; (B)
overall, with follow-up initiated at 6 mo after study entry; (C) by family history; (D) by family history, with follow-up initiated at 6 mo after study
entry; (E) by the BRCA2 ovarian cancer cluster region (OCCR, wide definition) [42_TD$DIFF] 2,22]; and (F) by the BRCA2 OCCR (wide definition) [42_TD$DIFF] 2,22] with follow-up
initiated at 6 mo after study entry. Family history was defined as having at least one first- or second-degree relative with a prostate cancer diagnosis
at the time of study entry.
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Table 2 – SIRs and absolute PCa risks for BRCA1 and BRCA2 mutation carriers overall and by age and PCa FH.
Gene Group n PYs OEs [52_TD$DIFF] R per
1000 PY (95% CI)
[53_TD$DIFF]EEs SIR (95% CI) Cumulative PCa risk,
% (95% CI)a
Overall
BRCA1 Age 19–44 yr 103 510.0 0 0.00 0.00 0.00 0
Age 45–54 yr 134 556.0 2 3.60 (0.90–14.4) 0.21 9.56 (2.39–38.2) 3.5 (0.87–13)
Age 55–64 yr 162 707.3 5 7.07 (2.92–17.1) 1.75 2.86 (1.18–6.94) 9.9 (4.8–20)
Age 65–74 yr 138 539.1 7 13.0 (6.15–27.4) 3.32 2.11 (1.00–4.46) 21 (13–34)
Age 75–84 yr 53 192.9 2 10.4 (2.57–41.9) 1.51 1.32 (0.33–5.33) 29 (17–45)
Age 19–64 yr 296 1773.3 7 3.95 (1.88–8.31) 1.96 3.57 (1.68–7.58) 10 (4.8–20)
Age 65–84 yr 153 731.9 9 12.3 (6.39–23.7) 4.84 1.86 (0.96–3.59) 29 (17–45)
Overall 376 2505.3 16 6.39 (3.91–10.4) 6.80 2.35 (1.43–3.88) 29 (17–45)
BRCA2 Age 19–44 yr 155 622.9 0 0.00 0.01 0.00 0
Age 45–54 yr 173 720.1 4 5.56 (2.05–15.0) 0.27 14.7 (5.43–39.8) 5.4 (2.1–14)
Age 55–64 yr 171 593.2 3 5.06 (1.63–15.7) 1.47 2.04 (0.65–6.36) 10 (5.0–21)
Age 65–74 yr 134 463.3 9 19.4 (9.93–38.0) 2.88 3.13 (1.60–6.12) 27 (17–41)
Age 75–84 yr 51 155.0 10 64.5 (33.2–125.4) 1.21 8.25 (4.25–16.0) 60 (43–78)
Age 19–64 yr 362 1936.2 7 3.62 (1.71–7.65) 1.75 3.99 (1.88–8.49) 10 (5.0–21)
Age 65–84 yr 153 618.2 19 30.7 (19.3–49.0) 4.09 4.64 (2.91–7.41) 60 (43–78)
Overall 447 2554.4 26 10.2 (6.92–15.0) 5.85 4.45 (2.99–6.61) 60 (43–78)
By PCa FHb
BRCA1 No FH 311 2110.0 13 6.16 (3.58–10.6) 5.55 2.34 (1.35–4.07) 31 (17–50)
FH 48 264.8 3 11.3 (3.54–36.3) 0.95 3.17 (0.97–10.4)c 28 (9.8–64)
BRCA2 No FH 344 1969.9 18 9.14 (5.75–14.5) 4.65 3.87 (2.40–6.23) 47 (31–65)
FH 87 481.4 7 14.5 (6.78–31.2) 0.96 7.31 (3.40–15.7)d –e
CI = conﬁdence interval; EEs = expected events; FH = family history; HR=hazard ratio[55_TD$DIFF]; IR = incidence rate; OEs = observed events; PCa =prostate cancer;
PY =person-year; SIR = standardised incidence ratio.
a
[56_TD$DIFF]Kaplan-Meier estimated cumulative PCa risk by the end of each age interval or age 85 yr.
b At least one first- or second-degree relative diagnosed with PCa.
c BRCA1 carriers: HR per affected first- or second-degree relative 1.33 (95% CI 0.42–4.20).
d BRCA2 carriers: HR per affected first- or second-degree relative[57_TD$DIFF]1.68 (95% CI 0.99–2.85).
e PCa risk estimate for age 85 yr not available because of the low number of individuals left in follow-up. At age 75 yr, the cumulative PCa risk estimate was 43%
(95% CI 18–80) for BRCA2 carriers with a PCa FH and 22% (95% CI 12–36) for BRCA2 carriers without a PCa FH.
Table 3 – SIRs and absolute PCa risks for BRCA2 mutation carriers by mutation location within the BRCA2 gene.
Mutation location n PYs OEs IR
per 1000 PY [58_TD$DIFF]
(95% CI)
EEs SIR (95% CI) Cumulative PCa [59_TD$DIFF]risk,
% (95% CI)a[54_TD$DIFF]
Hazard ratio
(95% conﬁdence interval)
[60_TD$DIFF]Unadjusted Adjusted
for FH
Excluding
AFMCsb
BRCA2 OCCR, wide deﬁnition [2,22]
50 to c.2830 or
c.6402 to 30
(non-OCCR)
267 1489.2 20 13.4 (8.64–20.9) 3.40 5.88 (3.75–9.22) 11 (4.3–28) Reference Reference Reference
30 (17–49)
83 (61–96)
c.2831 [62_TD$DIFF]to c.6401
(OCCR)
178 1054.4 6 5.69 (2.54–12.8) 2.44 2.46 (1.07–5.64) 10 [63_TD$DIFF](3.4–29) 0.37 (0.14-0.96) 0.40 (0.15-1.07) 0.43 (0.15-1.24)
22 (11–43)
22 (11–43)
Indeterminable 2
BRCA2 OCCR, narrow deﬁnition [64_TD$DIFF] 2,22]
50 to c.3846 or
c.6276 to 30
(non-OCCR)
284 1581.8 20 12.6 (8.14–19.7) 3.56 5.62 (3.59–8.81) 10 (4.0–26) Reference Reference Reference
29 (16–48)
80 (59–94)
c.3847 [62_TD$DIFF]to c.6275
(OCCR)
161 961.8 6 6.24 (2.78–14.0) 2.28 2.63 (1.14–6.04) 11 (3.7–31) 0.42 (0.16-1.09) 0.46 (0.17-1.22) 0.50 (0.17-1.45)
23 (11–45)
23 (11–45)
Indeterminable 2
BRCA2 PCCR [65_TD$DIFF] 13]
50 to c.6372 or
c.6493 to 30
(non-PCCR)
444 2540.0 26 10.2 (6.95–15.1) 5.83 4.46 (3.00–6.64) 10 (5.0–21) Reference
27 (17–41)
61 (43–79)
c.6373 [62_TD$DIFF]to c.6492
(PCCR)
3 14.4 0 0.00 0.02 0.00 0 Not done
0
0
AFMCs=Ashkenazi founder mutation carriers; CI = conﬁdence interval; EEs = expected events; FH= family history; HR=hazard ratio; IR = incidence rate;
OCCR=ovarian cancer cluster region; OEs = observed events; PCa =prostate cancer; PCCR=PCa cluster region; PY =person-year; SIR = standardised incidence
ratio.
a Kaplan-Meier estimated cumulative PCa risk by ages 65, 75, and 85yr, respectively.
b Carriers of c.5946delT.
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narrow definition of the OCCR (c.3847–c.6275) [42_TD$DIFF] 2,22] the
difference in PCa risk for mutations within and outside the
OCCR was attenuated (HR 0.42, 95% CI 0.16–1.09; Table 3).
The proportional hazards assumption was violated for this
model (Schoenfeld residuals test, p = 0.005); the corre-
sponding Kaplan-Meier curves revealed that the risks were
similar between OCCR and non-OCCR mutation carriers at
younger ages but deviated at older ages (Fig. 1E and 1[95_TD$DIFF] ). The
difference in risk between OCCR and non-OCCR mutation
carriers (wide definition) was not statistically significant
but was of similar magnitude after adjusting for family
history (adjusted HR 0.40, 95% CI 0.15–1.07) and after
omitting Ashkenazi mutation carriers (HR 0.43, 95% CI 0.15–
1.24; Table 3).
3.2. GS-specific PCa
For BRCA1 carriers, the SIR was higher for GS6 (SIR 3.50,
95% CI 1.67–7.35) than for GS7 PCa (SIR 1.80, 95% CI 0.89–
3.65). By contrast, for BRCA2 carriers the SIR was higher for
GS7 (SIR 5.07, 95% CI 3.20–8.02) than for GS6 PCa (SIR
3.03, 95% CI 1.24–7.44; Table 4). By age 85 yr, the absolute
risk was 12% (95% CI 5.0–23%) for GS6 and 16% (95% CI
6.4–30%) for GS7 PCa among BRCA1 carriers, and 9.3%
(95% CI 2.9–20%) for GS6 and 51% (95% CI 30%-69%) for
GS7 PCa among BRCA2 carriers.
3.3. PCa mortality
Two BRCA1 and four BRCA2 carriers died from their incident
PCa during follow-up. Compared to population PCa-specific
mortality rates, the SMR was 1.75 (95% CI 0.44–6.90) for
BRCA1 and 3.85 (95% CI 1.44–10.3) for BRCA2 carriers.
3.4. Sensitivity analyses
The estimated SIRs remained similar under alternative
inclusion or censoring assumptions (Table 5). Of the 42 PCa
diagnoses, nine occurred within the first 6 mo after study
entry (Supplementary Table 1). In the landmark analyses,
where follow-up was initiated at 6 or 12 mo after study
entry, SIRs were lower for both BRCA1 (6-mo landmark: SIRTable 4 – GS-specific [66_TD$DIFF]PCa SIRs for BRCA1 and BRCA2 mutation carriers
Gene n PYs Events with
[67_TD$DIFF]unknown GS
GS OEs EEs
BRCA1 373 2488.9 3
6 7 2.19
7 6 4.61
BRCA2 440 2537.4 7
6 4 1.83
7 15 4.02
EEs = expected events; GS =Gleason score; MIs =multiple imputations; OEs = ob
incidence ratio.
a Pooled estimates from 100 imputations using multivariate imputation by chaine
GS, prostate-specific antigen at diagnosis, clinical stage, diagnostic modality (scree
follow-up, and family history (number of affected first- and second-degree relati2.02, 95% CI 1.17–3.50; 12-mo landmark: SIR 2.15, 95% CI
1.24–3.73) and BRCA2 carriers (6-mo landmark: SIR 3.68,
95% CI 2.35–5.75; 12-mo landmark: SIR 3.37, 95% CI 2.08–
5.47) but remained statistically significant. In the 6-mo
landmark analysis, the estimated absolute PCa risk by age
85 yr was 26% (95% CI 15–43%) for BRCA1 and 55% (95% CI
36–75%) for BRCA2 carriers. When compared to a hypothet-
ical population with higher PCa incidence, the association
remained significant for BRCA2 carriers (adjustment factor
1.9: SIR 2.34, 95% CI 1.57–3.48). The overall association was
not significant for BRCA1 carriers (adjustment factor 1.9: SIR
1.24, 95% CI 0.75–2.04), but the association for ages <65yr
remained significantwith the lower adjustment factor of 1.6
(SIR 2.23, 95% CI 1.05–4.73). The corresponding absolute
risk by age 85 yr when adjusted by a factor of 1.9 was 17%
(95% CI 8–26%) for BRCA1 and 41% (95% CI 22–59%) for
BRCA2 mutation carriers. When the landmark analysis was
applied assuming higher population incidences, only the
overall association between BRCA2 mutations and PCa risk
remained significant (SIR 2.30, 95% CI 1.47–3.60; Table 5).
When follow-up was restricted to the period before
initiation of the IMPACT screening trial [76_TD$DIFF] 27], in addition to
the entire follow-up for participants from non–IMPACT-
recruiting centres, therewas no associationwith PCa risk for
BRCA1 carriers (SIR 0.74, 95% CI 0.18–3.04). However, this
was based on a small sample size and the 95% CI overlapped
with that for the estimate for BRCA1 carriers from IMPACT-
recruiting centres with follow-up after October 2005 (SIR
2.83, 95% CI 1.67–4.81). The point estimateswere similar for
BRCA2 carriers followed without potential overlap with the
IMPACT trial period and recruiting centres (SIR 3.57, 95% CI
1.29–9.85) and those whose follow-up potentially over-
lappedwith IMPACT (SIR 4.54, 95% CI 2.96–6.99). The SIR for
ages <65yr for BRCA2 carriers with no potential overlap
with IMPACT was 6.75 (95% CI 1.98–23.0; Table 5).
When follow-up was initiated 6 mo after baseline, the
SIRs for BRCA1 carriers were similar for GS6 (SIR 2.26, 95%
CI 0.86–5.91) and GS7 PCa (SIR 1.90, 95% CI 0.93–3.85), in
contrast to the main results. The difference in GS-specific
SIR estimates remained for BRCA2 carriers (GS6: SIR 2.01,
95% CI 0.60–6.80; GS7: SIR 4.39, 95% CI 2.63–7.31;
Table 4). On the basis of this analysis, the absolute risk by
age 85yr for BRCA1 carriers was 7.8% (95% CI 2.2–18%) for.
SIR (95% conﬁdence interval)
[68_TD$DIFF]Without imputations MIsa [61_TD$DIFF] MIs and 6-mo landmark
3.25 (1.54–6.88) 3.50 (1.67–7.35) 2.26 (0.86–5.91)
1.32 (0.59–2.98) 1.80 (0.89–3.65) 1.90 (0.93–3.85)
2.23 (0.83–5.97) 3.03 (1.24–7.44) 2.01 (0.60–6.80)
3.80 (2.27–6.38) 5.07 (3.20–8.02) 4.39 (2.63–7.31)
served events; [69_TD$DIFF]PCa = prostate cancer; PY =person-year; SIR = standardised
d equations. The following covariates were used for the imputation: [70_TD$DIFF]PCa status,
ning/clinical), mutation gene (BRCA1/2), year of birth, age at study entry, age at
ves).
Table 5 – Sensitivity analyses.
Sensitivity analysis Gene Group n PYs OEs [71_TD$DIFF] R per 1000 PY
(95% CI)
EEs SIR (95% CI) [72_TD$DIFF]Cumulative
PCa risk,
% (95% CI)a
Excluding men with
previous non-PCas
BRCA1 Age 19–64 yr 286 1724.5 7 4.06 (1.91–8.61) 1.90 3.68 (1.73–7.81) 10 (5.0–20)
Age 65–84 yr 141 659.6 9 13.6 (7.09–26.2) 4.32 2.08 (1.08–4.01) 32 (19–50)
Overall 355 2384.1 16 6.71 (4.09–11.0) 6.23 2.57 (1.56–4.23) 32 (19–50)
BRCA2 Age 19–64 yr 342 1859.8 7 3.76 (1.78–7.96) 1.62 4.32 (2.03–9.21) 11 (5.3–22)
Age 65–84 yr 110 454.0 11 24.2 (13.3–44.3) 2.95 3.72 (2.03–6.82) 60 (34–87)
Overall 390 2313.8 18 7.78 (4.90–12.4) 4.57 3.94 (2.45–6.32) 60 (34–87)
Censoring for non-
PCas in follow-up
BRCA1 Age 19–64 yr 296 1740.9 7 4.02 (1.91–8.46) 1.90 3.68 (1.74–7.81) 10 (5.0–20)
Age 65–84 yr 151 684.5 9 13.1 (6.84–25.3) 4.51 2.00 (1.04–3.85) 30 (18–48)
Overall 376 2425.4 16 6.60 (4.04–10.8) 6.41 2.50 (1.52–4.11) 30 (18–48)
BRCA2 Age 19–64 yr 362 1919.4 7 3.65 (1.72–7.71) 1.73 4.06 (1.91–8.63) 10 (5.1–21)
Age 65–84 yr 150 599.8 18 30.0 (18.6–48.5) 3.97 4.53 (2.80–7.32) 59 (42–78)
Overall 447 2519.2 25 9.92 (6.69–14.7) 5.70 4.39 (2.93–6.57) 59 (42–78)
Censoring all on June
30, 2016
BRCA1 Age 19–64 yr 296 1751.7 7 4.00 (1.90–8.41) 1.92 3.64 (1.72–7.72) 10 (4.9–20)
Age 65–84 yr 148 713.0 8 11.2 (5.62–22.4) 4.71 1.70 (0.85–3.40) 28 (17–44)
Overall 376 2464.7 15 6.09 (3.67–10.1) 6.64 2.26 (1.35–3.78) 28 (17–44)
BRCA2 Age 19–64 yr 362 1895.7 7 3.69 (1.75–7.81) 1.71 4.10 (1.93–8.74) 10 (5.1–21)
Age 65–84 yr 153 599.7 19 31.7 (19.9–50.6) 3.97 4.79 (3.00–7.65) 61 (43–79)
Overall 447 2495.4 26 10.4 (7.08–15.3) 5.67 4.58 (3.08–6.82) 61 (43–79)
Excluding missense
mutation carriers
BRCA1 Age 19–64 yr 288 1741.0 7 4.02 (1.91–8.46) 1.94 3.61 (1.70–7.65) 10 (4.9–20)
Age 65–84 yr 152 721.5 9 12.5 (6.48–24.0) 4.77 1.89 (0.98–3.64) 29 (18–45)
Overall 368 2462.5 16 6.50 (3.97–10.6) 6.71 2.38 (1.45–3.93) 29 (18–45)
BRCA2 Age 19–64 yr 358 1924.2 7 3.64 (1.72–7.69) 1.75 4.00 (1.88–8.50) 10 (5.0–21)
Age 65–84 yr 148 593.8 18 30.3 (18.8–48.9) 3.91 4.60 (2.85–7.43) 61 (43–79)
Overall 438 2517.9 25 9.93 (6.69–14.7) 5.67 4.41 (2.94–6.61) 61 (43–79)
Excluding Ashkenazi
founder mutation
carriersb
BRCA1 Age 19–64 yr 262 1535.8 5 3.26 (1.34–7.89) 1.64 3.05 (1.26–7.40) 8.2 (3.5–19)
Age 65–84 yr 134 623.6 7 11.2 (5.34–23.6) 4.14 1.69 (0.80–3.56) 27 (15–47)
Overall 332 2159.3 12 5.56 (3.15–9.81) 5.78 2.08 (1.17–3.68) 27 (15–47)
BRCA2 Age 19–64 yr 330 1769.3 6 3.39 (1.51–7.62) 1.55 3.86 (1.71–8.72) 9.8 (4.5–21)
Age 65–84 yr 136 533.0 19 35.6 (22.3–57.0) 3.53 5.38 (3.36–8.60) 65 (46–83)
Overall 405 2302.4 25 10.9 (7.32–16.1) 5.09 4.91 (3.28–7.36) 65 (46–83)
Follow-up initiated
6 mo after baseline
BRCA1 Age 19–64 yr 268 1631.6 5 3.06 (1.27–7.42) 1.84 2.72 (1.12–6.58) 7.3 (3.1–17)
Age 65–84 yr 149 691.7 8 11.6 (5.79–23.1) 4.59 1.74 (0.87–3.49) 26 (15–43)
Overall 352 2323.3 13 5.60 (3.24–9.68) 6.43 2.02 (1.17–3.50) 26 (15–43)
BRCA2 Age 19–64 yr 335 1761.7 5 2.84 (1.17–6.87) 1.61 3.10 (1.28–7.54) 8.5 (3.6–19)
Age 65–84 yr 141 577.2 15 26.0 (15.5–43.7) 3.83 3.92 (2.33–6.60) 55 (36–75)
Overall 414 2338.8 20 8.55 (5.51–13.3) 5.44 3.68 (2.35–5.75) 55 (36–75)
Follow-up initiated
12 mo after baseline
BRCA1 Age 19–64 yr 256 1500.4 5 3.33 (1.37–8.09) 1.73 2.89 (1.19–7.02) 7.8 (3.3–18)
Age 65–84 yr 144 650.3 8 12.3 (6.14–24.6) 4.33 1.85 (0.92–3.71) 27 (15–45)
Overall 341 2150.7 13 6.04 (3.49–10.5) 6.06 2.15 (1.24–3.73) 27 (15–45)
BRCA2 Age 19–64 yr 313 1600.4 5 3.12 (1.29–7.57) 1.49 3.37 (1.38–8.21) 8.9 (3.8–20)
Age 65–84 yr 136 535.7 12 22.4 (12.6–39.8) 3.56 3.37 (1.89–6.00) 51 (31–74)
Overall 400 2136.1 17 7.96 (4.95–12.8) 5.05 3.37 (2.08–5.47) 51 (31–74)
Comparison to PI
increased by a factor
of 1.6 [74_TD$DIFF] 26]]c[73_TD$DIFF]
BRCA1 Age 19–64 yr 296 1773.3 7 3.95 (1.88–8.31) 3.14 2.23 (1.05–4.73) 6.3 (1.6–11)
Age 65–84 yr 153 731.9 9 12.3 (6.39–23.7) 7.74 1.16 (0.60–2.24) 19 (8.8–30)
Overall 376 2505.3 16 6.39 (3.91–10.4) 10.9 1.47 (0.89–2.42) 19 (8.8–30)
BRCA2 Age 19–64 yr 362 1936.2 7 3.62 (1.71–7.65) 2.81 2.49 (1.17–5.31) 6.6 (1.7–11)
Age 65–84 yr 153 618.2 19 30.7 (19.3–49.0) 6.55 2.90 (1.82–4.63) 46 (27–65)
Overall 447 2554.4 26 10.2 (6.92–15.0) 9.35 2.78 (1.87–4.13) 46 (27–65)
Comparison to PI
increased by a factor
of 1.9 [75_TD$DIFF] 26]c
BRCA1 Age 19–64 yr 296 1773.3 7 3.95 (1.88–8.31) 3.72 1.88 (0.89–3.99) 5.4 (1.6–9.3)
Age 65–84 yr 153 731.9 9 12.3 (6.39–23.7) 9.19 0.98 (0.51–1.89) 17 (8.0–26)
Overall 376 2505.3 16 6.39 (3.91–10.4) 12.9 1.24 (0.75–2.04) 17 (8.0–26)
BRCA2 Age 19–64 yr 362 1936.2 7 3.62 (1.71–7.65) 3.33 2.10 (0.99–4.47) 5.6 (1.5–9.8)
Age 65–84 yr 153 618.2 19 30.7 (19.3–49.0) 7.77 2.44 (1.53–3.90) 41 (22–59)
Overall 447 2554.4 26 10.2 (6.92–15.0) 11.1 2.34 (1.57–3.48) 41 (22–59)
Follow-up initiated
6 mo after baseline,
and comparison to PI
increased by a factor
of 1.6 [26]c[75_TD$DIFF]
BRCA1 Age 19–64 yr 268 1631.6 5 3.06 (1.27–7.42) 2.94 1.70 (0.70–4.11) 4.8 (0.87–8.7)
Age 65–84 yr 149 691.7 8 11.6 (5.79–23.1) 7.34 1.09 (0.54–2.18) 18 (7.1–28)
Overall 352 2323.3 13 5.60 (3.24–9.68) 10.3 1.26 (0.73–2.19) 18 (7.1–28)
BRCA2 Age 19–64 yr 335 1761.7 5 2.84 (1.17–6.87) 2.58 1.94 (0.80–4.72) 5.5 (0.67–10)
Age 65–84 yr 141 577.2 15 26.0 (15.5–43.7) 6.12 2.45 (1.46–4.12) 40 (19–61)
Overall 414 2338.8 20 8.55 (5.51–13.3) 8.70 2.30 (1.47–3.60) 40 (19–61)
All participants until
October 1, 2005, and
participants from
centres not recruiting
to IMPACT [76_TD$DIFF] 27] after
October 1, 2005
BRCA1 Age 19–64 yr 115 497.5 0 0.00 1.38 0.00 0
Age 65–84 yr 54 208.3 2 9.60 (2.31–39.9) 3.07 1.05 (0.24–4.55) 11 (2.9–39)
Overall 147 705.8 2 2.83 (0.69–11.6) 2.72 0.74 (0.18–3.04) 11 (2.9–39)
BRCA2 Age 19–64 yr 113 439.7 3 6.82 (2.11–22.0) 0.67 6.75 (1.98–23.0) 20 (6.6–50)
Age 65–84 yr 34 108.7 1 9.20 (1.27–66.7) 0.68 1.48 (0.20–10.7) 36 (13–75)
Overall 134 548.4 4 7.29 (2.69–19.8) 1.12 3.57 (1.29–9.85) 36 (13–75)
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Table 5 (Continued )
Sensitivity analysis Gene Group n PYs OEs [71_TD$DIFF] R per 1000 PY
(95% CI)
EEs SIR (95% CI) [72_TD$DIFF]Cumulative
PCa risk,
% (95% CI)a
Participants from
centres recruiting to
IMPACT [76_TD$DIFF] 27] after
October 1, 2005
BRCA1 Age 19–64 yr 241 1275.8 7 5.49 (2.61–11.5) 1.42 4.93 (2.33–10.4) 14 (6.7–26)
Age 65–84 yr 120 523.7 7 13.4 (6.43–27.8) 3.52 1.99 (0.95–4.15) 34 (20–53)
Overall 310 1799.5 14 7.78 (4.63–13.1) 4.94 2.83 (1.67–4.81) 34 (20–53)
BRCA2 Age 19–64 yr 298 1496.4 4 2.67 (1.00–7.17) 1.42 2.81 (1.04–7.60) 7.7 (2.9–19)
Age 65–84 yr 129 509.5 18 35.3 (21.8–57.2) 3.42 5.27 (3.25–8.54) 62 (44–80)
Overall 372 2006.0 22 11.0 (7.16–16.8) 4.84 4.54 (2.96–6.99) 62 (44–80)
CI = conﬁdence interval; EEs = expected events[77_TD$DIFF]; IR = incidence rate; OEs =observed events; PCa =prostate cancer; PI =population incidence; PY=person-year;
SIR = standardised incidence ratio.
a
[56_TD$DIFF]Kaplan-Meier estimated cumulative prostate cancer risk by the end of each age interval or age 85 yr.
b BRCA1: c.68_69delAG and c.5266dupC; BRCA2: c.5946delT.
c The absolute risks were estimated using a Kaplan-Meier estimator weighted by the inverse of the adjustment factor for men with events.
E U RO P E AN URO L OGY 7 7 ( 2 0 2 0 ) 2 4 – 3 532GS6 and 18% (95% CI 7.1–33%) for GS7 PCa. For BRCA2
carriers the corresponding risk was 7.1% (95% CI 1.4–19%)
and 47% (95% CI 25–66%), respectively.
4. Discussion
We estimated the risk of PCa for male BRCA1 and BRCA2
mutation carriers using data from a large prospective
cohort. The results substantiate previous reports from
retrospective studies of a strong association between BRCA2
mutations and PCa risk, and give some support for a similar
but weaker association for mutations in the BRCA1 gene,
particularly at younger ages.
Depending on the assumptions, we found that BRCA2
carriers are at a two to five times higher risk of PCa
compared to men in the general population, which is
consistent with previous RR estimates in the range 2–6 [80_TD$DIFF] 3–
13]. Our BRCA2 RR estimates did not vary substantially with
age, in contrast to previous studies suggesting higher RRs at
younger ages [81_TD$DIFF] 4,6,13–15]. However, the higher RR estimate
at ages <65yr for the subset of BRCA2 carriers with no
potential overlap with the IMPACT screening trial suggests
that the similarities in associations by age might be due to
potential screening effects. However, owing to the small
number of events at younger ages, the precision of the
estimates was low. In line with previous studies [96_TD$DIFF] 3,5,7–
10,12,13,16–21], our findings indicate that BRCA1mutations
are at most associated with a moderate PCa risk at younger
ages, with RR estimates in the range 2–4 for ages<65yr. The
evidence for an association is weak at older ages, with our
RR estimates varying between 1 and 2. Much larger studies
are required to clarify the association between BRCA1
mutations and PCa risk.
The estimated cumulative risk of developing PCa by age
85yr was 29% (95% CI 17–45%) for BRCA1 and 60% (95% CI
43–78%) for BRCA2 carriers. However, absolute PCa risks
depend on the screening regimen used, and the PCa risks
were lower in analyses that assessed the impact of
potentially prevalent cancers and the excess PCa risk among
PSA-screened individuals. Although our RR estimates are
similar to previous estimates, the absolute risk estimates
from the present study are higher than estimates fromretrospective studies. Previous absolute PCa risk estimates
by ages 65–80 yr range from 3% to 9% for BRCA1 carriers [97_TD$DIFF]
[7,17,21] and from 15% to 34% for BRCA2 carriers [98_TD$DIFF]
[4,6,7,13,15,22] (Supplementary Table 2 [99_TD$DIFF]). It is plausible that
absolute risk estimates based on historical data are not
representative of the absolute PCa risks for BRCA1/2 carriers
in the PSA testing era. Prospective risk estimates may be
more informative for counselling current mutation carriers.
Only two previous prospective studies on PCa risk for male
BRCA1/2 carriers have been reported and were limited by
small sample sizes and wide CIs for their RR estimates, and
neither presented absolute risk estimates. In a prospective
cohort of 62 carriers from the USA, BRCA2 mutations were
associatedwith higher PCa risk (SIR 4.89, 95% CI 1.96–10.08)
but there was no significant association for BRCA1 carriers
(SIR 3.81, 95% CI 0.77–11.13) [100_TD$DIFF] 12]. An Israeli study observed
only three prospective PCas in 210 unaffected BRCA1/2
carriers (median follow-up 5.1 yr) and chose not to report a
prospective RR estimate [101_TD$DIFF] 24].
The results indicate that PCa risks for mutation carriers
increase with the number of affected relatives, consistent
with findings in the general population [102_TD$DIFF] 28]. This is also
consistent with the hypothesis that other familial factors
modify PCa risks for mutation carriers, and with recent
observations that common PCa susceptibility genetic
variants [103_TD$DIFF] 29] modify PCa risk for BRCA1/2 carriers [104_TD$DIFF] 30]. This
emphasises the importance of considering family history
and other risk-modifying genetic factors when counselling
male BRCA1/2 carriers. However, it is possible that mutation
carriers with a family history of PCa are more likely to be
screened or biopsied than mutation carriers without a PCa
family history; this may also partly explain the higher risk
observed.
We found that BRCA1 carriers were at higher risk of
GS6 disease, but after omitting diagnoses in the initial
6 mo after study recruitment, the associations with high-
and low-grade diseasewere similar. BRCA1 carrierswere not
at a significantly higher risk of PCa mortality, although the
CI for the SMR estimate was wide. A lack of association
between BRCA1 mutations and PCa grade is in line with
published data [82_TD$DIFF] 8,9], and the higher SIR for GS6 disease
might reflect a higher propensity for diagnosing indolent
E U RO P E AN U RO LOGY 7 7 ( 2 0 2 0 ) 2 4 – 3 5 33low-grade tumours that would not have been detected in
the absence of the discovery of a deleterious mutation.
Conversely, our results suggest that BRCA2 mutations are
associated with a more aggressive PCa phenotype; the
associationwas stronger for GS7 than for GS6 tumours.
Furthermore, we observed a significant association be-
tween BRCA2 mutations and PCa mortality. Associations
with high-grade disease and PCa mortality are consistent
with previous reports for BRCA2 carriers [82_TD$DIFF] 8,9], and suggest
that the BRCA2 findings are less affected by screening
effects.
BRCA2 mutations both within and outside the OCCR
were associated with elevated PCa risk. However, our
results suggest that carriers of mutations within the OCCR
are at comparatively lower risk than carriers of mutations
outside the OCCR, consistent with previous findings [105_TD$DIFF]
[6,22]. They are also consistent with reports of lower PCa
risk for carriers of the BRCA2 c.5946delT Ashkenazi Jewish
founder mutation, which is located in the OCCR [106_TD$DIFF] 23]. Con-
versely, the results are in contrast to a UK study that
reported a HR of 2.92 (95% CI 1.54–5.54) for OCCR
compared to non-OCCR mutations [107_TD$DIFF] 10]. However, this
study was based on a retrospective cohort of BRCA2
carriers and their relatives and the analyses were not
adjusted for the ascertainment process.
Strengths of our study include the nationwide recruit-
ment of mutation carriers, which supports the generalisa-
bility of our findings. Furthermore, this is the largest
prospective cohort of men with deleterious BRCA1/2 muta-
tions to date, and the prospective study design allows for
direct estimation of both relative and absolute risks. We
have provided risk estimates by family history andmutation
location.
Although this is the largest prospective study reported
to date, the precision of our estimates is still limited by a
moderate sample size and the number of incident PCas and
PCa deaths. The results by GS are limited by potential
inaccuracies in tumour grading based on biopsies;
however, since mutation carriers were recruited through
a UK-wide study and SIRs were computed relative to
national GS-specific incidences (which will have similar
inaccuracies), variability in pathological grading is unlikely
to have resulted in a systematic bias. Other limitations
include possible oversampling of menwith a family history
of PCa as a result of the recruitment through clinical
genetics centres. While this allowed us to obtain estimates
applicable to mutation carriers both with and without a
family history, the overall risk might be somewhat
overestimated compared to average BRCA1/2 carriers in
the population. In addition, known mutation carriers who
undergo genetic counselling may receive enhanced
screening compared to men from the general population.
More specifically, during the study period the IMPACT
screening trial [76_TD$DIFF] 27] also recruited male BRCA1/2 carriers,
and therefore some overlap between IMPACT and EM-
BRACE is likely. Given the background prevalence of
indolent PCas that are undetectable in the absence of
screening [108_TD$DIFF] 31] and our observed clustering of PCa
diagnoses shortly after study entry, it is plausible thatsome of these PCas would not have been discovered in the
absence of diagnostic measures taken as a result of the
discovery of a mutation. When we initiated follow-up at
6 or 12 mo after study entry, the estimated RRs were
attenuated for both BRCA1 and BRCA2 carriers, but
remained statistically significant. Furthermore, known
mutation carriers may undergo a different screening
regimen over an extended period of time in comparison
to men in the general population [93_TD$DIFF] 25]. To assess this we
compared the PCa incidence observed to that expected
from population incidences adjusted by screening effect
sizes estimated in the ERSPC trial [75_TD$DIFF] 26]. The SIRs for BRCA2
carriers remained significant, but the excess risk for BRCA1
carriers was not consistently significant, and was signifi-
cant only for ages <65 yr. This adjustment is limited by the
assumption of a constant average screening effect on the
population PCa incidences [109_TD$DIFF]based on published ERSPC
estimates [75_TD$DIFF] 26]. The ERSPC data also suggest that the effect
of screening may be time-dependent, with a probable
decrease in screening effect sizes with time since initiation
of screening [75_TD$DIFF] 26]. This time dependence was not consid-
ered in our analysis and can result in potential overesti-
mation of SIRs if the true effect of screening on population
incidences is higher than the assumed average during the
follow-up period. However, our adjustment used the
highest published average PSA screening effect size from
ERSPC, and assumes that no screening occurs in the general
population, which is unlikely given the rates of opportu-
nistic screening [110_TD$DIFF] 32] and may result in an attenuation of
the SIR estimates. After using both a 6-month landmark to
control for the detection of prevalent PCas [111_TD$DIFF], and higher
population incidences, the SIRs remained significant only
for BRCA2 carriers. However, these may represent extreme
overadjustments. Finally, whenwe restricted the follow-up
to [112_TD$DIFF]centres and/or time periods not overlapping with the
IMPACT recruitment, we found no association between
BRCA1 mutations and PCa risk. This might suggest that the
association observed for BRCA1 carriers is driven by
screening-induced diagnoses of indolent tumours, but
caution is needed in the interpretation as the sample size
used for this subgroup analysis was small. By contrast, the
strength of the association was similar for BRCA2 carriers
regardless of potential overlap with IMPACT. Assuming
that clinically significant tumours are likely to be diag-
nosed regardless of screening regimen, this observation is
consistent with the hypothesis that BRCA2 mutations are
associated with a risk of more aggressive disease. It
provides further evidence that the association between
BRCA2 mutations and PCa risk is unlikely to be explained
by screening effects.
5. Conclusions
This prospective analysis substantiates previous reports on
the RR of PCa for BRCA1 and BRCA2 mutation carriers from
retrospective studies, and provides direct estimates of
absolute PCa risk by family history and mutation char-
acteristics. The results will be informative in the counselling
of men who carry BRCA1 or BRCA2 mutations.
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